Acumen Pharmaceuticals, Inc. (ABOS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 86.79M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 9.80M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -105.42M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $86.79M | (m) | $9.80M | $-105.42M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $96.10M | (m) | $9.77M | $-114.61M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $104.89M | (m) | $9.85M | $-123.83M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $118.93M | (m) | $9.78M | $-138.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $124.21M | (m) | $9.65M | $-143.98M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $106.61M | (m) | $9.63M | $-126.61M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $93.80M | (m) | $9.63M | $-114.02M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $72.52M | (m) | $8.93M | $-92.91M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $56.45M | (m) | $8.19M | $-76.68M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $46.05M | (m) | $7.24M | $-65.78M | $1.58M | (m) | (m) | -41.60× | Reported |
| 2023-12-31 | $42.32M | (m) | $6.14M | $-61.14M | $581.00K | (m) | (m) | -105.23× | Reported |
| 2023-09-30 | $39.77M | (m) | $5.40M | $-56.90M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $36.90M | (m) | $4.64M | $-52.23M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $35.09M | (m) | $3.83M | $-49.17M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $32.36M | (m) | $3.06M | $-45.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $27.29M | (m) | $2.54M | $-39.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $20.78M | (m) | $2.00M | $-31.97M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $15.71M | (m) | $1.41M | $-25.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $12.30M | (m) | $922.00K | $-19.58M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.00M | (m) | $154.00K | $-7.91M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |